41ON.F · Outlook Therapeutics, Inc

-

Please sign in to comment on 41ON.F

1 Comment

Admin

4 years, 1 month ago

Outlook Therapeutics, Inc is currently in a long term uptrend where the price is trading 46.7% above its 200 day moving average.

From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.0.

Outlook Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 12.9% to $-14M since the same quarter in the previous year.

Finally, its free cash flow fell by 99.7% to $-13M since the same quarter in the previous year.

Based on the above factors, Outlook Therapeutics, Inc gets an overall score of 3/5.

Exchange	F
CurrencyCode	EUR
ISIN	US69012T2069
Sector	Healthcare
Industry	Biotechnology

Beta	0.84
Dividend Yield	0.0%
Market Cap	347M
PE Ratio	None
Target Price	7

ABOUT

Outlook Therapeutics, Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

41ON.F · Outlook Therapeutics, Inc

-

Outlook Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Outlook Therapeutics, Inc using a moving average strategy